» Articles » PMID: 16564524

Osteogenic Actions of the Anti-diabetic Drug Metformin on Osteoblasts in Culture

Overview
Journal Eur J Pharmacol
Specialty Pharmacology
Date 2006 Mar 28
PMID 16564524
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

An association has been previously established between uncompensated diabetes mellitus and the loss of bone mineral density and/or quality. In this study, we evaluated the effects of metformin on the growth and differentiation of osteoblasts in culture. Treatment of two osteoblast-like cells (UMR106 and MC3T3E1) with metformin (25-500 microM) for 24 h led to a dose-dependent increase of cell proliferation. Metformin also promoted osteoblastic differentiation: it increased type-I collagen production in both cell lines and stimulated alkaline phosphatase activity in MC3T3E1 osteoblasts. In addition, metformin markedly increased the formation of nodules of mineralization in 3-week MC3T3E1 cultures. Metformin induced activation and redistribution of phosphorylated extracellular signal-regulated kinase (P-ERK) in a transient manner, and dose-dependently stimulated the expression of endothelial and inducible nitric oxide synthases (e/iNOS). These results show for the first time a direct osteogenic effect of metformin on osteoblasts in culture, which could be mediated by activation/redistribution of ERK-1/2 and induction of e/iNOS.

Citing Articles

Improvement of osteogenic differentiation potential of placenta-derived mesenchymal stem cells by metformin via AMPK pathway activation.

Manochantr S, Meesuk L, Chadee N, Suwanprateeb J, Tantrawatpan C, Kheolamai P Stem Cell Res Ther. 2024; 15(1):417.

PMID: 39533406 PMC: 11559138. DOI: 10.1186/s13287-024-04014-6.


Bone Fragility in Diabetes and its Management: A Narrative Review.

Leungsuwan D, Chandran M Drugs. 2024; 84(9):1111-1134.

PMID: 39103693 DOI: 10.1007/s40265-024-02078-5.


Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis.

Saadi M, Das R, Mullath Ullas A, Powell D, Wilson E, Myrtziou I Int J Mol Sci. 2024; 25(14.

PMID: 39063229 PMC: 11277066. DOI: 10.3390/ijms25147988.


Metformin treatment prevents experimental metabolic syndrome-induced femoral bone marrow adiposity in rats.

Lasalvia S, Sedlinsky C, Schurman L, McCarthy A, Wanionok N Rev Peru Med Exp Salud Publica. 2024; 41(1):28-36.

PMID: 38808841 PMC: 11149757. DOI: 10.17843/rpmesp.2024.411.13333.


Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures.

Wikarek A, Grabarczyk M, Klimek K, Janoska-Gawronska A, Suchodolska M, Holecki M Medicina (Kaunas). 2024; 60(3).

PMID: 38541119 PMC: 10972440. DOI: 10.3390/medicina60030393.